Optimizing HIV Treatment: A Focus on Comorbidities, Access, and Long-Term Health
For decades, antiretroviral therapy (ART) has transformed HIV from a life-threatening illness into a manageable chronic condition. However, as individuals with HIV live longer, healthier lives, a new focus emerges: optimizing ART not just for viral suppression, but for the prevention and management of associated comorbidities. This requires a proactive, patient-centered approach that addresses cardiovascular risk, leverages innovative therapies, and tackles systemic barriers to equitable access.
Beyond viral Suppression: A Shift in Focus
While achieving and maintaining virologic suppression remains paramount,the landscape of HIV care is evolving. We’re seeing a growing population of individuals living with HIV who are aging and developing conditions traditionally associated with older age, such as cardiovascular disease, kidney disease, and osteoporosis.This necessitates a more holistic approach to ART management, considering the long-term impact of treatment choices on overall health.
The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 (SGLT2) inhibitors, traditionally used for diabetes and obesity, is being explored in the context of HIV care.While these medications may be considered for patients with these conditions, their off-label use is not currently recommended. For otherwise healthy, virologically suppressed patients, a strong foundation of monitoring and extensive lifestyle support remains the cornerstone of preventative care.
Proactive Comorbidity Management During ART switches
When considering a switch in ART regimen for a virologically suppressed patient, a key opportunity arises to proactively address potential comorbidities. My approach centers on minimizing cardiovascular risk.
Specifically, I often recommend transitioning patients off abacavir due to its documented association with an increased risk of myocardial infarction. Similarly, protease inhibitors, known to negatively impact lipid profiles, are often replaced with alternatives.
Crucially, I advocate for early statin initiation in patients with HIV, even at lower 10-year cardiovascular risk thresholds (exceeding 5%) than typically used in the general population. The landmark REPRIEVE trial demonstrated a significant 35% reduction in cardiovascular events with statin use in this population.This proactive approach is vital, as individuals with HIV often present with higher baseline cardiovascular risk.
For patients already living with comorbidities, a coordinated care model is essential. With nearly half of my patients now over 60, collaboration with geriatricians is invaluable in addressing issues like frailty, fall risk, and polypharmacy. Furthermore, integrating HIV care with behavioral health and addiction treatment, often through the support of community health workers, is critical for patients facing adherence challenges related to substance use or mental health conditions. This multidisciplinary, team-based approach is essential to maintaining viral suppression and improving overall outcomes.
Navigating the Obstacles to ART Optimization
Despite the advancements in ART, several obstacles hinder optimal regimen management for virologically suppressed patients.
The most significant barrier is often insurance coverage, particularly for long-acting injectable ART. the complexities of billing – whether through medical or pharmacy benefits – vary drastically by insurer and state, leading to frustrating delays that are simply not encountered with oral medications. Our team relies heavily on dedicated clinical pharmacists to navigate prior authorizations, complex billing processes, and benefit logistics.
Policy and geographic disparities also play a significant role. Access to newer therapies is frequently enough smoother in states like Massachusetts compared to those with more restrictive Medicaid policies. At a systemic level, limited access to streamlined regimens keeps patients on older therapies that can compromise adherence and increase the risk of adverse events.
looking ahead, the introduction of agents like lenacapavir underscores the need for consistent national policies, simplified benefit structures, and robust care coordination to ensure equitable and timely access to these innovative treatments.
The Impact of Access Disparities on Clinical Outcomes
The reality is that only approximately 65% of people with HIV in the US achieve virologic suppression, a stark contrast to the nearly 90% seen in many other parts of the world. This gap is largely attributable to our fragmented healthcare system and the resulting disparities in access to care.
Given that the vast majority of new HIV transmissions occur from individuals who are not virally suppressed, increasing suppression rates is paramount to ending the HIV epidemic.
Optimizing ART – through uninterrupted access to effective regimens, expanded use of long-acting injectables for those with adherence challenges, and innovative care models like home administration – is a crucial step. Raising suppression rates to 80-90% provides the tools to dramatically reduce new infections. However,achieving this requires a concerted effort to build the necessary infrastructure and address the systemic inequities that currently limit access to care.
Conclusion
The future of HIV care lies in a proactive, patient
Related reading